211 related articles for article (PubMed ID: 22581225)
1. Risk factors of amphotericin B toxicty in the nonneonatal pediatric population.
Dutta A; Palazzi DL
Pediatr Infect Dis J; 2012 Sep; 31(9):910-4. PubMed ID: 22581225
[TBL] [Abstract][Full Text] [Related]
2. Impact of liposomal amphotericin B on renal function in critically ill patients with renal function impairment.
Alvarez-Lerma F; Soriano MC; Rodríguez M; Catalán M; Llorente AM; Vidart N; Garitacelaya M; Maraví E; Fernández E; Alvarado F; López M; Alvarez-Sánchez B; Espinosa J; Quintana E;
Rev Esp Quimioter; 2012 Sep; 25(3):206-15. PubMed ID: 22987267
[TBL] [Abstract][Full Text] [Related]
3. Nephrotoxicity and other adverse events among inpatients receiving liposomal amphotericin B or amphotericin B lipid complex.
Wade RL; Chaudhari P; Natoli JL; Taylor RJ; Nathanson BH; Horn DL
Diagn Microbiol Infect Dis; 2013 Jul; 76(3):361-7. PubMed ID: 23774005
[TBL] [Abstract][Full Text] [Related]
4. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.
Walsh TJ; Finberg RW; Arndt C; Hiemenz J; Schwartz C; Bodensteiner D; Pappas P; Seibel N; Greenberg RN; Dummer S; Schuster M; Holcenberg JS
N Engl J Med; 1999 Mar; 340(10):764-71. PubMed ID: 10072411
[TBL] [Abstract][Full Text] [Related]
5. Implementation of clinical practice policy on the continuous intravenous administration of amphotericin B deoxycholate.
Maharom P; Thamlikitkul V
J Med Assoc Thai; 2006 Nov; 89 Suppl 5():S118-24. PubMed ID: 17718252
[TBL] [Abstract][Full Text] [Related]
6. Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia.
Shehab N; DePestel DD; Mackler ER; Collins CD; Welch K; Erba HP
Pharmacotherapy; 2007 Jul; 27(7):970-9. PubMed ID: 17594202
[TBL] [Abstract][Full Text] [Related]
7. [Liposomal amphotericin B in the treatment of severe fungal infections. Results of a clinical cohort trial].
Rieger CT; Dittmer M; Ostermann H
Dtsch Med Wochenschr; 2007 Oct; 132(40):2062-6. PubMed ID: 17899499
[TBL] [Abstract][Full Text] [Related]
8. A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations.
Cannon JP; Garey KW; Danziger LH
Pharmacotherapy; 2001 Sep; 21(9):1107-14. PubMed ID: 11560200
[TBL] [Abstract][Full Text] [Related]
9. Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety.
Hamill RJ; Sobel JD; El-Sadr W; Johnson PC; Graybill JR; Javaly K; Barker DE
Clin Infect Dis; 2010 Jul; 51(2):225-32. PubMed ID: 20536366
[TBL] [Abstract][Full Text] [Related]
10. The novel lipid delivery system of amphotericin B: drug profile and relevance to clinical practice.
Rust DM; Jameson G
Oncol Nurs Forum; 1998; 25(1):35-48. PubMed ID: 9460772
[TBL] [Abstract][Full Text] [Related]
11. Occurrence and improvement of renal dysfunction and serum potassium abnormality during administration of liposomal amphotericin B in patients with hematological disorders: A retrospective analysis.
Yamazaki H; Kondo T; Aoki K; Yamashita K; Takaori-Kondo A
Diagn Microbiol Infect Dis; 2018 Feb; 90(2):123-131. PubMed ID: 29203252
[TBL] [Abstract][Full Text] [Related]
12. Amphotericin B deoxycholate (d-AMB) use in cases with febrile neutropenia and fungal infections: lower toxicity with suitable premedication.
Oto OA; Paydas S; Disel U; Yavuz S; Seydaoglu G
Mycoses; 2007 Mar; 50(2):135-9. PubMed ID: 17305778
[TBL] [Abstract][Full Text] [Related]
13. Oral voriconazole versus intravenous low dose amphotericin B for primary antifungal prophylaxis in pediatric acute leukemia induction: a prospective, randomized, clinical study.
Mandhaniya S; Swaroop C; Thulkar S; Vishnubhatla S; Kabra SK; Xess I; Bakhshi S
J Pediatr Hematol Oncol; 2011 Dec; 33(8):e333-41. PubMed ID: 22042283
[TBL] [Abstract][Full Text] [Related]
14. Adverse effects of amphotericin B in children; a retrospective comparison of conventional and liposomal formulations.
Andrew EC; Curtis N; Coghlan B; Cranswick N; Gwee A
Br J Clin Pharmacol; 2018 May; 84(5):1006-1012. PubMed ID: 29352486
[TBL] [Abstract][Full Text] [Related]
15. Analysis of Hypokalemia as a Side Effect of Liposomal Amphotericin in Pediatric Patients.
Kobayashi R; Keino D; Hori D; Sano H; Suzuki D; Kishimoto K; Kobayashi K
Pediatr Infect Dis J; 2018 May; 37(5):447-450. PubMed ID: 28945677
[TBL] [Abstract][Full Text] [Related]
16. [Current treatment of candidemia in non-neutropenic patients. Amphotericin B or fluconazole? A retrospective study of 62 consecutive patients].
Cobo Reinoso P; Aguado García JM; Lumbreras Bermejo C; Pérez Vela JL; Caballero Cubedo R; Sanz Sanz F; Noriega Rodríguez AR
Rev Clin Esp; 1997 Dec; 197(12):799-803. PubMed ID: 9477669
[TBL] [Abstract][Full Text] [Related]
17. Continuous and 4 h infusion of amphotericin B: a comparative study involving high-risk haematology patients.
Peleg AY; Woods ML
J Antimicrob Chemother; 2004 Oct; 54(4):803-8. PubMed ID: 15308606
[TBL] [Abstract][Full Text] [Related]
18. Comparison of nephrotoxicity associated to different lipid formulations of amphotericin B: a real-life study.
Falci DR; da Rosa FB; Pasqualotto AC
Mycoses; 2015 Feb; 58(2):104-12. PubMed ID: 25590436
[TBL] [Abstract][Full Text] [Related]
19. Deoxycholate amphotericin B and nephrotoxicity in the pediatric setting.
Bes DF; Rosanova MT; Sberna N; Arrizurieta E
Pediatr Infect Dis J; 2014 Aug; 33(8):e198-206. PubMed ID: 24618932
[TBL] [Abstract][Full Text] [Related]
20. Once-weekly liposomal amphotericin B as Candida prophylaxis in very low birth weight premature infants: a prospective, randomized, open-label, placebo-controlled pilot study.
Arrieta AC; Shea K; Dhar V; Cleary JP; Kukreja S; Morris M; Vargas-Shiraishi OM; Ashouri N; Singh J
Clin Ther; 2010 Feb; 32(2):265-71. PubMed ID: 20206784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
